8-K: 4D Molecular Therapeutics Announces Positive Interim Data for 4D-150 in Wet AMD

4D Molecular Therapeutics reports positive 52-week interim data from its Phase 2b PRISM clinical trial for 4D-150 in wet AMD, showing significant reduction in supplemental injections and improved visual acuity.

Summary

• 4D Molecular Therapeutics announced positive initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial, evaluating 4D-150 for wet age-related macular degeneration (wet AMD).
• The data, with a cutoff of January 15, 2025, showed an 83% reduction in supplemental aflibercept injections, representing 0.97 mean injections per patient over 52 weeks, compared to 6.0 injections projected with on-label aflibercept.
• 70% of patients required 0-1 injection, and 57% were injection-free.
• Patients experienced improved and maintained best corrected visual acuity (BCVA) of +2.2 letters.
• Durable central subfield thickness (CST) improvement with fewer fluctuations was observed, with a reduction of -11 m overall and -13 m in supplemental injection-free patients.
• In a subgroup of recently diagnosed patients (n=15), there was a 94% reduction in supplemental aflibercept injections, representing 0.33 mean injections per patient over 52 weeks.
• 87% of recently diagnosed patients required 0-1 injection, and 80% were injection-free.
• This subgroup also showed improved and maintained BCVA of +3.1 letters and a CST improvement of -10 m overall and -20 m in supplemental injection-free patients.
• 4D-150 continues to be well tolerated during up to three years of follow up in all patients treated with 3E10 vg/eye.
• Aqueous humor concentrations showed durable and stable aflibercept expression for up to two years, consistently within the projected therapeutic range.
• The company expects to initiate the 4FRONT-1 and 4FRONT-2 trials in Q1 and Q3 2025, respectively.
• Two-year Phase 1/2a and 18-month Phase 2b PRISM data are expected in Q4 2025.
• Primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 are expected in H2 2027.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data, suggesting a promising future for 4D-150 and the company. The reduction in injections and improved visual acuity are strong indicators of potential market success.

Positives

• Significant reduction in the need for supplemental aflibercept injections in wet AMD patients.
• Improved and maintained visual acuity in treated patients.
• Durable and stable aflibercept expression observed.
• 4D-150 continues to be well tolerated during up to three years of follow up in all patients treated with 3E10 vg/eye.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks are detailed in the company's filings with the Securities and Exchange Commission.

Future Outlook

The company anticipates initiating the 4FRONT-1 and 4FRONT-2 trials in 2025 and expects to announce data from ongoing clinical trials in the coming years.

Industry Context

The results are significant in the context of the broader market for wet AMD treatments, where frequent injections are a major burden for patients. 4D-150's potential to reduce injection frequency could provide a significant competitive advantage.

Comparison to Industry Standards

• The current standard of care for wet AMD often involves regular intravitreal injections of anti-VEGF drugs like aflibercept (Eylea) or ranibizumab (Lucentis), typically every 4-8 weeks.
• Regeneron's Eylea is a leading treatment, and 4D-150's aim to reduce the injection burden could position it as a strong competitor if Phase 3 trials confirm these results.
• Other companies like Roche (Vabysmo) are also developing treatments with extended durability, but gene therapy approaches like 4D-150 offer a potentially longer-lasting solution.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial data.
• Patients with wet AMD could benefit from a treatment that reduces the frequency of injections.
• The company's employees may be motivated by the progress of 4D-150.

Next Steps

• Initiate 4FRONT-1 and 4FRONT-2 trials in Q1 and Q3 2025, respectively.
• Announce two-year Phase 1/2a and 18-month Phase 2b PRISM data in Q4 2025.
• Report primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 in H2 2027.

Key Dates

Keywords

4D-150, wet AMD, aflibercept, clinical trial, PRISM, 4D Molecular Therapeutics, gene therapy, ophthalmology